06-03-2013, 11:52 AM
Dr.Reddy’s Laboratories Ltd
Reddy’s Laboratories.pptx (Size: 108.76 KB / Downloads: 44)
Background
Founded in 1984 by Dr. Anji Reddy
India’s second biggest pharma company; headquarters in Hyderabad
Produces and sells active pharmaceutical ingredients, finished dosages and biologics
Manufactures ulcer medicines, antibiotics, pain relievers, antidepressants and cardiovascular drugs
100 countries, focusing on Europe, India, US and Russia
Extensive R & D in diabetes, cancer, cardio vascular diseases, bacterial infections
120 medications and 60 active pharma ingredients for drug manufacture
Overview of FY 2011-12
Revenue - Rs.9,674 crore
Net profit - Rs.1,531 crore
Growth rate - 42%
Global generics key markets of North America and Russia which grew by 68 per cent and 22 per cent, respectively
Revival of pharma services and active ingredients sectors, good contribution from the over-the-counter business and limited competition
Revenues from Europe at Rs.826 crore declined by 2% due to happenings in the German market and serious pricing pressures
2011-12 : launch of 16 products in the U.S., 23 in India, 14 in Russia, 28 in Europe and 60 in rest of the world, including South Africa
R&D expenditure which remained at 6% of sales in 2012 expected to be 7-8%
Outlook for 2012-13
DRL expected to maintain a similar growth pace, depending on the approval of products in time
Consistent inventory, liquidity predicts stability in operational efficiency
PE ratio predicts high perception amongst investors
EPS stability maintains investor interest
Fall in net profits by 2% keeping with gobal scenario and unsatisfactory domestic sales
Capital expenditure for three months FY13 - $35 million